CEO: Jeffrey W. Albers

Sector: Healthcare
Industry:Biotechnology

Exchange: Nasdaq Global Select

Country: USA

Description: Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667.


Key numbers

Market Capitalization:3990282200
Shares Outstanding: 49202000
Float: 47807173
Next Earning Date:2020-02-24
TTm EPS: -7.7758
TTm Dividend Rate:
200 days moving average:81.18
50 days moving average: 77.27
One day percent Change: 0.17



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,